Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) (EUCRU) currently reports a debt-to-equity ratio of 0.01. That is below the sector sector average of 0.2. Use the charts on this page to explore Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War)'s debt-to-equity ratio history and peer comparisons.

Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War)'s debt-to-equity ratio of 0.01 is lower than the its sector sector average of 0.2. That is roughly 96.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The debt-to-equity ratio is a valuation multiple that relates Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War)'s market price to a fundamental measure such as earnings, sales, or book value. At 0.01, EUCRU can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current debt-to-equity ratio of 0.01, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 0.2. From there, open related valuation or income-statement pages for Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War), and consider following EUCRU for alerts when major investors trade the stock.